Cargando…

LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies

BACKGROUND: LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Saj, Michal, Bilinska, Zofia T, Tarnowska, Agnieszka, Sioma, Agnieszka, Bolongo, Pierrette, Sobieszczanska-Malek, Malgorzata, Michalak, Ewa, Golen, Dorota, Mazurkiewicz, Lukasz, Malek, Lukasz, Walczak, Ewa, Fidzianska, Anna, Grzybowski, Jacek, Przybylski, Andrzej, Zielinski, Tomasz, Korewicki, Jerzy, Tesson, Frederique, Ploski, Rafal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666888/
https://www.ncbi.nlm.nih.gov/pubmed/23702046
http://dx.doi.org/10.1186/1471-2350-14-55
_version_ 1782271401793683456
author Saj, Michal
Bilinska, Zofia T
Tarnowska, Agnieszka
Sioma, Agnieszka
Bolongo, Pierrette
Sobieszczanska-Malek, Malgorzata
Michalak, Ewa
Golen, Dorota
Mazurkiewicz, Lukasz
Malek, Lukasz
Walczak, Ewa
Fidzianska, Anna
Grzybowski, Jacek
Przybylski, Andrzej
Zielinski, Tomasz
Korewicki, Jerzy
Tesson, Frederique
Ploski, Rafal
author_facet Saj, Michal
Bilinska, Zofia T
Tarnowska, Agnieszka
Sioma, Agnieszka
Bolongo, Pierrette
Sobieszczanska-Malek, Malgorzata
Michalak, Ewa
Golen, Dorota
Mazurkiewicz, Lukasz
Malek, Lukasz
Walczak, Ewa
Fidzianska, Anna
Grzybowski, Jacek
Przybylski, Andrzej
Zielinski, Tomasz
Korewicki, Jerzy
Tesson, Frederique
Ploski, Rafal
author_sort Saj, Michal
collection PubMed
description BACKGROUND: LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and in vitro. METHODS: Between January, 2008 and June, 2012 two patient populations were screened for the presence of LMNA mutations by direct sequencing: 66 dilated cardiomyopathy patients including 27 heart transplant recipients and 39 dilated cardiomyopathy patients with heart failure referred for heart transplantation evaluation, and 44 consecutive dilated cardiomyopathy patients, referred for a family evaluation and mutation screening. RESULTS: We detected nine non-synonymous mutations including three novel mutations: p.Ser431*, p.Val256Gly and p.Gly400Argfs*11 deletion. There were 25 carriers altogether in nine families. The carriers were mostly characterized by dilated cardiomyopathy and heart failure with conduction system disease and/or complex ventricular arrhythmia, although five were asymptomatic. Among the LMNA mutation carriers, six underwent heart transplantation, fourteen ICD implantation and eight had pacemaker. In addition, we obtained ultrastructural images of cardiomyocytes from the patient carrying p.Thr510Tyrfs*42. Furthermore, because the novel p.Val256Gly mutation was found in a sporadic case, we verified its pathogenicity by expressing the mutation in a cellular model. CONCLUSIONS: In conclusion, in the two referral centre populations, the screening revealed five mutations among 66 heart transplant recipients or patients referred for heart transplantation (7.6%) and four mutations among 44 consecutive dilated cardiomyopathy patients referred for familial evaluation (9.1%). Dilated cardiomyopathy patients with LMNA mutations have poor prognosis, however considerable clinical variability is present among family members.
format Online
Article
Text
id pubmed-3666888
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36668882013-05-30 LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies Saj, Michal Bilinska, Zofia T Tarnowska, Agnieszka Sioma, Agnieszka Bolongo, Pierrette Sobieszczanska-Malek, Malgorzata Michalak, Ewa Golen, Dorota Mazurkiewicz, Lukasz Malek, Lukasz Walczak, Ewa Fidzianska, Anna Grzybowski, Jacek Przybylski, Andrzej Zielinski, Tomasz Korewicki, Jerzy Tesson, Frederique Ploski, Rafal BMC Med Genet Research Article BACKGROUND: LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and in vitro. METHODS: Between January, 2008 and June, 2012 two patient populations were screened for the presence of LMNA mutations by direct sequencing: 66 dilated cardiomyopathy patients including 27 heart transplant recipients and 39 dilated cardiomyopathy patients with heart failure referred for heart transplantation evaluation, and 44 consecutive dilated cardiomyopathy patients, referred for a family evaluation and mutation screening. RESULTS: We detected nine non-synonymous mutations including three novel mutations: p.Ser431*, p.Val256Gly and p.Gly400Argfs*11 deletion. There were 25 carriers altogether in nine families. The carriers were mostly characterized by dilated cardiomyopathy and heart failure with conduction system disease and/or complex ventricular arrhythmia, although five were asymptomatic. Among the LMNA mutation carriers, six underwent heart transplantation, fourteen ICD implantation and eight had pacemaker. In addition, we obtained ultrastructural images of cardiomyocytes from the patient carrying p.Thr510Tyrfs*42. Furthermore, because the novel p.Val256Gly mutation was found in a sporadic case, we verified its pathogenicity by expressing the mutation in a cellular model. CONCLUSIONS: In conclusion, in the two referral centre populations, the screening revealed five mutations among 66 heart transplant recipients or patients referred for heart transplantation (7.6%) and four mutations among 44 consecutive dilated cardiomyopathy patients referred for familial evaluation (9.1%). Dilated cardiomyopathy patients with LMNA mutations have poor prognosis, however considerable clinical variability is present among family members. BioMed Central 2013-05-23 /pmc/articles/PMC3666888/ /pubmed/23702046 http://dx.doi.org/10.1186/1471-2350-14-55 Text en Copyright © 2013 Saj et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Saj, Michal
Bilinska, Zofia T
Tarnowska, Agnieszka
Sioma, Agnieszka
Bolongo, Pierrette
Sobieszczanska-Malek, Malgorzata
Michalak, Ewa
Golen, Dorota
Mazurkiewicz, Lukasz
Malek, Lukasz
Walczak, Ewa
Fidzianska, Anna
Grzybowski, Jacek
Przybylski, Andrzej
Zielinski, Tomasz
Korewicki, Jerzy
Tesson, Frederique
Ploski, Rafal
LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
title LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
title_full LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
title_fullStr LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
title_full_unstemmed LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
title_short LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
title_sort lmna mutations in polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666888/
https://www.ncbi.nlm.nih.gov/pubmed/23702046
http://dx.doi.org/10.1186/1471-2350-14-55
work_keys_str_mv AT sajmichal lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT bilinskazofiat lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT tarnowskaagnieszka lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT siomaagnieszka lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT bolongopierrette lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT sobieszczanskamalekmalgorzata lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT michalakewa lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT golendorota lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT mazurkiewiczlukasz lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT maleklukasz lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT walczakewa lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT fidzianskaanna lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT grzybowskijacek lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT przybylskiandrzej lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT zielinskitomasz lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT korewickijerzy lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT tessonfrederique lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies
AT ploskirafal lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies